Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.40 |
| ▸ | MTNR1A | P48039 | 10/20 | 0.39 |
| ▸ | MTNR1B | P49286 | 9/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.39 |
| ▸ | NQO2 | P16083 | 1/20 | 0.39 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.38 |
| ▸ | PTGIR | P43119 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30389458 | 0.83 | PTGIR (0.41) | SIGMAR1UCHL1NR3C1PTGIR | |
| SCHEMBL18440160 | 0.83 | PTGIR (0.41) | TRPV1MTNR1AMTNR1BSIGMAR1NR3C1 | |
| SCHEMBL3720005 | 0.80 | MTNR1A (0.38) | MTNR1AMTNR1BNQO2EPHX1 | |
| SCHEMBL20438820 | 0.80 | FPR3 (0.39) | MTNR1AMTNR1BNQO2EPHX1 | |
| SCHEMBL7884554 | 0.79 | MTNR1A (0.45) | MTNR1AMTNR1BNQO2EPHX1 | |
| SCHEMBL13974252 | 0.78 | TAS1R3 (0.43) | UCHL1 | |
| SCHEMBL29771900 | 0.78 | TAS1R3 (0.43) | UCHL1 | |
| SCHEMBL13974108 | 0.78 | TAS1R3 (0.43) | UCHL1 | |
| SCHEMBL10175565 | 0.77 | TRPV1 (0.50) | TRPV1MTNR1AMTNR1BSIGMAR1NQO2 | |
| SCHEMBL20699943 | 0.76 | THRB (0.39) | UCHL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230055376-A1 | 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE | ARENA PHARMACEUTICALS, INC. | 2023-02-23 | — | — | US | disclosed |
| EP-3328835-B1 | 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE | ARENA PHARM INC (US) | 2022-10-12 | — | — | EP | disclosed |
| US-11395824-B2 | 5-HT2C receptor agonists and compositions and methods of use | ARENA PHARMACEUTICALS, INC. (US) | 2022-07-26 | — | — | US | disclosed |
| US-20180214455-A1 | 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE | ARENA PHARMACEUTICALS, INC. | 2018-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180214455-A1 | 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE | HTR2C, HTR2A, HCRTR2 | TRPV1 907/4885MTNR1A 131/4885MTNR1B 121/4885 |
| US-20230055376-A1 | 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE | HTR2C, HTR2A, HCRTR2 | TRPV1 907/4885MTNR1A 131/4885MTNR1B 121/4885 |
| US-11395824-B2 | 5-HT2C receptor agonists and compositions and methods of use | HTR2C, HTR2A, HCRTR2 | TRPV1 907/4885MTNR1A 131/4885MTNR1B 121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.